Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-771 in Japanese Subjects with CIDP and MMN
NCT05084053Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Primary completion
- Oct 2025
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of immunoglobulin g + hyaluronidase in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), sponsored by Takeda. Started Jan 2022; status: completed.
02
Drugs
immunoglobulin g + hyaluronidase
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT05084053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084053.